Akeso,Inc._德赢vwin官网ac德赢vwin【官方合作伙伴】 Akeso,Inc._德赢vwin官网ac德赢vwin【官方合作伙伴】


Tech platform

ACE Platform

Akeso Comprehensive Exploration platform (“ACE Platform”), encompassing comprehensive drug discovery and development functionalities, including target validation, antibody drug discovery and development, CMC, and GMP-compliant manufacturing. Our ACE Platform also possesses robust in-house manufacturing capability that is compliant with international GMP standards regulated by the NMPA, the FDA and the EMA.

TETRABOGY Technology

Our antibody discovery capabilities are driven by innovative technologies, such as our proprietary TETRABODY technology and our expertise in crystallography and structure-based antibody design and engineering which facilitate our antibody humanization and optimization. In addition to discovery, our CMC function also contributes to the successful build-up of our drug pipeline. Notably, our TETRABODY technology addresses major recurrent CMC challenges in the development and manufacture of bi-specific antibodies.

FlexFactory™ technology

Our Zhongshan facility is the first biopharmaceutical factory in the south China region that uses GE Healthcare’s FlexFactory™ technology, which provides centralized control and a disposable bioreactor lining system. This facility also provides GMP-compliant manufacturing scale-up, with 200 L, 500 L and 1,000 L disposable bioreactors, for a total capacity of 1,700 L. To expand this capacity, we are also installing two additional 1,000 L ofbioreactor capacity. Our Zhongshan facility also features a 6,000 vial/hour (10 mL and 2 mL vials) fill/finish line. This manufacturing facility also features a comprehensive and robust quality system for commercial production. This facility has approximately 3,200 square meters of floor space.

Commercialization Manufacturing Under Construction

This facility is being built on a piece of land of 56,573 square meters to accommodate our future growth. We plan to install eight 2,000 L bioreactors, two fill/finish lines for vials and pre-filled syringes and a development lab and pilot plant, with an anticipated annual production capacity of two million units. We expect this facility to serve as our bio-analysis center for comprehensive quality control and micro- testing functions. We plan to invest a total of RMB600 million to RMB800 million for the building of this facility, and expect to complete building the facility and commence operation in late 2020 or early 2021.